utidelone + fluoropyrimidine + platinum

utidelone + fluoropyrimidine + platinum is a combination chemotherapy regimen being developed by Beijing Biostar Pharmaceuticals Co., Ltd. for the first-line treatment of locally advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. The regimen consists of utidelone (UTD2), an oral next-generation genetically engineered epothilone analog that acts as a microtubule-stabilizing agent, combined with a fluoropyrimidine (such as capecitabine or 5-fluorouracil) and a platinum-based agent (such as oxaliplatin). Utidelone functions similarly to taxanes by inhibiting microtubules but is designed to overcome multidrug resistance and offer a better safety profile, particularly regarding hematologic toxicity. This combination is currently being evaluated in a Phase II/III clinical trial (NCT06841679) to assess its efficacy and safety, potentially including the addition of PD-1 inhibitors depending on local approvals.

Other names

Utidelone + CAPOXUtidelone + FOLFOXUTD2 + chemotherapy